{"id":"r-mabhdi-and-abvd","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Cardiotoxicity"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Peripheral neuropathy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"R-mabHDI appears to be an investigational monoclonal antibody designed to work synergistically with ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine), a standard chemotherapy regimen for Hodgkin lymphoma. The combination likely leverages immunomodulation and epigenetic targeting to improve treatment efficacy. ABVD provides direct cytotoxic effects while the mAb component may enhance immune recognition and tumor cell death.","oneSentence":"R-mabHDI is a monoclonal antibody targeting histone deacetylase inhibition combined with ABVD chemotherapy to enhance anti-tumor immune response and cytotoxicity in lymphomas.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:31:07.211Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hodgkin lymphoma (in combination with ABVD)"}]},"trialDetails":[{"nctId":"NCT00816959","phase":"PHASE3","title":"Study Evaluating the Effect of R-mabHDI in Lymphocytic Predominant Hodgkin's Lymphoma","status":"UNKNOWN","sponsor":"American Scitech International","startDate":"2011-07","conditions":"Hodgkin's Lymphoma","enrollment":1200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1473,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["R-mabHDI"],"phase":"phase_3","status":"active","brandName":"R-mabHDI and ABVD","genericName":"R-mabHDI and ABVD","companyName":"American Scitech International","companyId":"american-scitech-international","modality":"Small molecule","firstApprovalDate":"","aiSummary":"R-mabHDI and ABVD are treatments studied for Hodgkin's Lymphoma, with R-mabHDI specifically evaluated in a Phase III study for patients with lymphocytic predominant Hodgkin's Lymphoma. ABVD is a chemotherapy regimen that consists of the small molecule drugs adriamycin, bleomycin, vinblastine, and dacarbazine.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}